Tert-butyl n-(3,4-difluorophenyl)carbamate, 97%, 5g

Methyl 3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate, 95%, 1g

Hydroxyde de potassium, min 85%, Ph.Eur., en pastilles, 2,5 kg, emballage plastique.

7-Hydroxy-1,2,3,4-tetrahydro-8H-pyrido[1,2-a]pyrazin-8-one, 98%, 1g

ethyl 4-oxo-4-(4-thiomethylphenyl)butyrate, 97.0%, 250mg

(5,6-Dimethyl-9-oxo-xanthen)-4-acetic acid, 95.0%, 25mg

O-ALLYLHYDROXYLAMINE HCL, 97.0%, 25g

Brevianamide F, 97.0%, 100mg

N1,N2-Bis(4-hydroxy-2,6-dimethylphenyl)oxalamide, 97.0%, 250g

(S)-3-((tert-Butoxycarbonyl)amino)-3-(2-nitrophenyl)propanoic acid, 95.0%, 1g

Methyl 4-(4-cyanophenoxy)benzoate, 97%, 100mg

N-Cyanodiphenyl imidocarbonate, 97.0%, 100g

7-Bromo-2,3,4,5-tetrahydro-1H-benzo[c]azepin-1-one, 97%, 250mg